Nicox S.A. (NICXF)
USD 0.25
(-60.7%)
USD 0.25
(-60.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.88 Million EUR | 29.72% |
| 2022 | -29.7 Million USD | 40.27% |
| 2021 | -49.74 Million USD | -124.62% |
| 2020 | -22.14 Million USD | -4.26% |
| 2019 | -21.23 Million USD | -15.49% |
| 2018 | -18.39 Million EUR | -408.32% |
| 2017 | -3.61 Million EUR | 80.99% |
| 2016 | -19.03 Million EUR | 31.87% |
| 2015 | -27.93 Million EUR | -20.65% |
| 2014 | -23.15 Million EUR | -30.15% |
| 2013 | -17.79 Million EUR | -74.63% |
| 2012 | -10.18 Million EUR | 38.84% |
| 2011 | -16.66 Million EUR | 62.09% |
| 2010 | -43.95 Million EUR | 27.17% |
| 2009 | -60.35 Million EUR | 18.32% |
| 2008 | -73.88 Million EUR | -129.86% |
| 2007 | -32.14 Million EUR | -30.16% |
| 2006 | -24.69 Million EUR | -59.25% |
| 2005 | -15.5 Million EUR | -12.52% |
| 2004 | -13.78 Million EUR | 29.24% |
| 2003 | -19.47 Million EUR | -24.13% |
| 2002 | -15.69 Million EUR | -36.16% |
| 2001 | -11.52 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -20.88 Million EUR | 29.72% |
| 2023 Q2 | -6.6 Million USD | -84.38% |
| 2023 Q1 | -3.58 Million EUR | 66.68% |
| 2022 Q1 | -9.4 Million EUR | 70.65% |
| 2022 Q2 | -17 Million USD | -80.78% |
| 2022 Q3 | -5.26 Million EUR | 69.02% |
| 2022 Q4 | -10.75 Million USD | -104.1% |
| 2022 FY | -29.7 Million USD | 40.27% |
| 2021 Q2 | -11.71 Million EUR | -70.6% |
| 2021 Q3 | -18.55 Million EUR | -58.45% |
| 2021 Q4 | -32.04 Million EUR | -72.68% |
| 2021 FY | -49.74 Million USD | -124.62% |
| 2021 Q1 | -6.86 Million EUR | -96.67% |
| 2020 FY | -22.14 Million USD | -4.26% |
| 2020 Q4 | -3.49 Million EUR | -70.56% |
| 2020 Q3 | -2.04 Million EUR | 85.99% |
| 2020 Q1 | -8.04 Million EUR | 55.71% |
| 2020 Q2 | -14.6 Million EUR | -81.48% |
| 2019 FY | -21.23 Million USD | -15.49% |
| 2019 Q4 | -18.17 Million EUR | -83.48% |
| 2019 Q3 | -9.9 Million EUR | -2219.36% |
| 2019 Q1 | -421.2 Thousand EUR | 93.15% |
| 2019 Q2 | -426.99 Thousand EUR | -1.38% |
| 2018 Q3 | -6.23 Million EUR | -39.59% |
| 2018 Q2 | -4.46 Million EUR | 5.21% |
| 2018 FY | -18.39 Million EUR | -408.32% |
| 2018 Q4 | -6.15 Million EUR | 1.32% |
| 2018 Q1 | -4.71 Million EUR | 0.0% |
| 2017 Q1 | -6.49 Million EUR | -300.1% |
| 2017 Q2 | -6.94 Million EUR | -7.06% |
| 2017 FY | -3.61 Million EUR | 80.99% |
| 2016 Q4 | 3.24 Million EUR | -6.3% |
| 2016 Q2 | -7.16 Million EUR | 2.49% |
| 2016 Q1 | -7.34 Million EUR | -43.81% |
| 2016 Q3 | 3.46 Million EUR | 148.31% |
| 2016 FY | -19.03 Million EUR | 31.87% |
| 2015 Q4 | -5.11 Million EUR | 2.68% |
| 2015 FY | -27.93 Million EUR | -20.65% |
| 2015 Q3 | -5.25 Million EUR | 8.82% |
| 2015 Q2 | -5.75 Million EUR | -3.69% |
| 2015 Q1 | -5.55 Million EUR | 0.0% |
| 2014 FY | -23.15 Million EUR | -30.15% |
| 2014 Q2 | -7.62 Million EUR | 0.64% |
| 2014 Q1 | -7.67 Million EUR | -77.56% |
| 2013 Q4 | -4.32 Million EUR | -1.74% |
| 2013 FY | -17.79 Million EUR | -74.63% |
| 2013 Q3 | -4.24 Million EUR | 12.42% |
| 2013 Q2 | -4.84 Million EUR | -10.71% |
| 2013 Q1 | -4.37 Million EUR | 21.23% |
| 2012 FY | -10.18 Million EUR | 38.84% |
| 2012 Q3 | -4.27 Million EUR | 5.38% |
| 2012 Q4 | -5.55 Million EUR | -29.97% |
| 2012 Q1 | 4.17 Million EUR | 166.52% |
| 2012 Q2 | -4.52 Million EUR | -208.29% |
| 2011 FY | -16.66 Million EUR | 62.09% |
| 2011 Q3 | -2.6 Million EUR | 30.28% |
| 2011 Q1 | -4.06 Million EUR | 33.56% |
| 2011 Q2 | -3.73 Million EUR | 8.08% |
| 2011 Q4 | -6.27 Million EUR | -141.16% |
| 2010 Q3 | -10.34 Million EUR | 49.15% |
| 2010 Q1 | -7.15 Million EUR | 0.0% |
| 2010 FY | -43.95 Million EUR | 27.17% |
| 2010 Q4 | -6.11 Million EUR | 40.9% |
| 2010 Q2 | -20.33 Million EUR | -184.23% |
| 2009 Q1 | -11.24 Million EUR | 0.0% |
| 2009 FY | -60.35 Million EUR | 18.32% |
| 2008 FY | -73.88 Million EUR | -129.86% |
| 2007 FY | -32.14 Million EUR | -30.16% |
| 2006 FY | -24.69 Million EUR | -59.25% |
| 2005 FY | -15.5 Million EUR | -12.52% |
| 2004 FY | -13.78 Million EUR | 29.24% |
| 2003 FY | -19.47 Million EUR | -24.13% |
| 2002 FY | -15.69 Million EUR | -36.16% |
| 2001 FY | -11.52 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -446.766% |
| Skye Bioscience, Inc. | -37.64 Million USD | 44.531% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 132.059% |
| Nascent Biotech, Inc. | -2.08 Million USD | -900.2% |
| Qrons Inc. | -789.34 Thousand USD | -2545.351% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4925.765% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -199.033% |
| BioStem Technologies, Inc. | -8.48 Million USD | -146.152% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2140.14% |
| CSL Limited | 2.64 Billion USD | 100.79% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 66.643% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 139.414% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1947.157% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1463.615% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3201.829% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -31.563% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 72.145% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -217.528% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -7537.472% |
| SQZ Biotechnologies Company | -79.46 Million USD | 73.723% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -621.928% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1046.975% |
| Mesoblast Limited | -87.95 Million USD | 76.26% |
| Marizyme, Inc. | -65.34 Million USD | 68.046% |
| Genus plc | 7.9 Million USD | 364.316% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -91.714% |
| Pharming Group N.V. | -10.54 Million USD | -97.962% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -862.341% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -462.795% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -136.104% |
| ContraFect Corporation | -65.15 Million USD | 67.951% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -327.358% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1108.772% |
| IMV Inc. | -36.48 Million USD | 42.769% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -159.08% |
| MultiCell Technologies, Inc. | -380.07 USD | -5493887.95% |
| ONE Bio Corp. | 8.67 Million USD | 340.658% |
| Accustem Sciences Inc. | -3.74 Million USD | -457.359% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 59.605% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -1547.892% |
| Q BioMed Inc. | -2.05 Million USD | -917.546% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -459.362% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -777.032% |
| Biomind Labs Inc. | -1.21 Million USD | -1619.565% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 65.038% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -573.197% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -164.213% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -971.233% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -139329.754% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -258.949% |
| GB Sciences, Inc. | -1.36 Million USD | -1433.477% |
| Alpha Cognition Inc. | -13.77 Million USD | -51.613% |
| HST Global, Inc. | -146.21 Thousand USD | -14181.513% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1089.956% |
| Halberd Corporation | -79.67 Thousand USD | -26107.39% |
| Enzolytics Inc. | -2.17 Million USD | -859.238% |
| Agentix Corp. | -1.37 Million USD | -1419.49% |
| Resverlogix Corp. | -3.61 Million USD | -478.421% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -558.408% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 92.923% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 21407.143% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 401.548% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -425.574% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -590.022% |
| AVAX Technologies, Inc. | -6.41 Million USD | -225.571% |
| Zenith Capital Corp. | -10.59 Million USD | -97.065% |
| Genscript Biotech Corporation | -95.47 Million USD | 78.13% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -89741.666% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -403.65% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -34447.964% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -941.387% |
| Kadimastem Ltd | -3.3 Million USD | -531.342% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1877.261% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -4630.962% |
| LadRx Corporation | 400.44 Thousand USD | 5314.475% |
| Cell Source, Inc. | -5.32 Million USD | -292.411% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2140.14% |
| NovAccess Global Inc. | -4.76 Million USD | -337.831% |
| Affymax, Inc. | -14.42 Million USD | -44.766% |
| Itoco Inc. | -1.86 Million USD | -1017.231% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -370.024% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1151.108% |
| Mobile Lads Corp. | -2.26 Million USD | -822.594% |
| CytoDyn Inc. | -49.84 Million USD | 58.105% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -26320.609% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -9053.235% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -2117.776% |
| SYBLEU INC | -180.3 Thousand USD | -11480.997% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1194.755% |
| International Stem Cell Corporation | -131 Thousand USD | -15839.695% |
| Bioxytran, Inc. | -4.28 Million USD | -387.874% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -38374.72% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -725.255% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 56.563% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -887.748% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -2574.01% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -559.122% |
| Neutra Corp. | -233.46 Thousand USD | -8843.953% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -2.908% |
| PureTech Health plc | -65.69 Million USD | 68.216% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 1.813% |
| IXICO plc | -1.17 Million USD | -1672.581% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -110.346% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 63.449% |
| CSL Limited | 2.64 Billion USD | 100.79% |
| Cellectis S.A. | -103.17 Million USD | 79.761% |